Finite-sample Testing of Average Out-of-specification-rate Claims: A Learn-then-test Framework for Design-space Candidates

Abstract Purpose Predictive performance can identify a design-space candidate but cannot establish its quality claim. We developed a finite-sample procedure for a prespecified average out-of-specification (OOS) rate claim under a reference plan. Methods Construction data ranked operating conditions and defined a finite nested candidate family. Independent calibration data provided exact one-sided tests for the full candidates. Holm’s procedure controlled the family-wise error rate (FWER) at 0.05. The case study compared Parteck M100 and M200 on a finite grid of 315 measured setpoints per grade. Partial least squares (PLS) and random forest (RF) scores were evaluated on matched splits. Exact hypergeometric tests conditioned on the known OOS labels among construction setpoints. Results Among target candidate masses 0.10, 0.55, and 1.00 under the reference plan, the largest supported candidate contained 174 M100 setpoints and 32 M200 setpoints at a tolerated average OOS rate of 0.15. Matched outcomes showed a grade-associated difference before score modeling. PLS and RF preserved the grade ordering of supported mass, although membership differed, especially for M200. In simulation, empirical FWER for the full-candidate Holm procedure remained below 0.05, whereas the unadjusted comparator reached 0.105. The fixed M200 candidate was retained in M100; the fixed M100 candidate was not retained in M200. Conclusion The procedure supports an average OOS-rate claim for a candidate selected from a prespecified family under a stated reference plan. The procedure does not provide pointwise assurance. Candidate-family design, score-model choice, retention, and recertification must be interpreted separately.

Authors

Institutions

Publication Details

Journal
Journal of Pharmaceutical Innovation
Published
2026-09-04
DOI
https://doi.org/10.1007/s12247-026-10985-1
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Finite-sample Testing of Average Out-of-specification-rate Claims: A Learn-then-test Framework for Design-space Candidates

Manabu Kano, Kanta Sato
Journal of Pharmaceutical Innovation
Statistical Methods in Clinical Trials
article

Finite-sample Testing of Average Out-of-specification-rate Claims: A Learn-then-test Framework for Design-space Candidates

Manabu Kano, Kanta Sato
article en

Abstract

Abstract Purpose Predictive performance can identify a design-space candidate but cannot establish its quality claim. We developed a finite-sample procedure for a prespecified average out-of-specification (OOS) rate claim under a reference plan. Methods Construction data ranked operating conditions and defined a finite nested candidate family. Independent calibration data provided exact one-sided tests for the full candidates. Holm’s procedure controlled the family-wise error rate (FWER) at 0.05. The case study compared Parteck M100 and M200 on a finite grid of 315 measured setpoints per grade. Partial least squares (PLS) and random forest (RF) scores were evaluated on matched splits. Exact hypergeometric tests conditioned on the known OOS labels among construction setpoints. Results Among target candidate masses 0.10, 0.55, and 1.00 under the reference plan, the largest supported candidate contained 174 M100 setpoints and 32 M200 setpoints at a tolerated average OOS rate of 0.15. Matched outcomes showed a grade-associated difference before score modeling. PLS and RF preserved the grade ordering of supported mass, although membership differed, especially for M200. In simulation, empirical FWER for the full-candidate Holm procedure remained below 0.05, whereas the unadjusted comparator reached 0.105. The fixed M200 candidate was retained in M100; the fixed M100 candidate was not retained in M200. Conclusion The procedure supports an average OOS-rate claim for a candidate selected from a prespecified family under a stated reference plan. The procedure does not provide pointwise assurance. Candidate-family design, score-model choice, retention, and recertification must be interpreted separately.

Journal of Pharmaceutical InnovationVol. 22(1)
Kyoto University (JP), Daiichi Sankyo (United Kingdom) (GB)
Daiichi Sankyo Company, Daiichi Sankyo Europe
Openalex Percentile: Top 8%
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.